Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.46 |
| ▸ | FADS1 | O60427 | 3/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 2/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.34 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5066722 | 0.83 | PRKD3 (0.51) | TRPA1GRM4FADS1AURKAAURKB | |
| SCHEMBL13639076 | 0.80 | TRPA1 (0.49) | TRPA1GRM4FADS1ADRA2AAURKA | |
| SCHEMBL13636079 | 0.77 | GRM4 (0.53) | TRPA1GRM4FADS1 | |
| SCHEMBL12510676 | 0.77 | TRPA1 (0.54) | TRPA1GRM4FADS1ADRA2ALRRK2 | |
| SCHEMBL802749 | 0.74 | TRPA1 (0.50) | TRPA1GRM4FADS1ADRA2AAURKA | |
| SCHEMBL12510675 | 0.73 | TRPA1 (0.49) | TRPA1GRM4FADS1ADRA2AAURKA | |
| SCHEMBL14164020 | 0.71 | FADS1 (0.42) | TRPA1GRM4FADS1ADRA2AAURKA | |
| SCHEMBL802362 | 0.71 | FADS1 (0.42) | TRPA1GRM4FADS1ADRA2AMAPK10 | |
| SCHEMBL29882003 | 0.70 | TRPA1 (0.75) | TRPA1GRM4FADS1ADRA2AAURKA | |
| SCHEMBL4741513 | 0.70 | TRPA1 (0.75) | TRPA1GRM4FADS1ADRA2AAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304414-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-06 | — | — | US | disclosed |
| US-20080287444-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-11-20 | — | — | US | disclosed |
| US-7427681-B2 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287444-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | AURKC, AURKA, CDK3 | TRPA1 4743/4885GRM4 4721/4885FADS1 2083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.